Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pathologic Complete Response × Folfox protocol × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 27 Colonic Neoplasms 19 Rectal Neoplasms 11 Carcinoma, Hepatocellular 7 Neoplasm Metastasis 5 Stomach Neoplasms 2 Neoplastic Cells, Circulating 2 Neoplasms 2 Liver Neoplasms 2 Recurrence 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Oligometastatic Gastric Adenocarcinoma 1 Neuroendocrine Tumors 1 Neoplasms, Second Primary 1 Neoplasm, Residual 1 Neoplasm Recurrence, Local 1 Margins of Excision 1 Locally Advanced Rectal Cancer 1 Gastro-enteropancreatic neuroendocrine tumor 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Biliary Tract Neoplasms 1

Interventions

Cyclophosphamide 3 Epirubicin 2 Docetaxel 2 Carboplatin 2 Capecitabine 2 Azacitidine 2 venetoclax 1 tegafur-gimeracil-oteracil 1 taxane 1 sargramostim 1 ruxolitinib 1 rucaparib 1 pirarubicin 1 pertuzumab 1 pembrolizumab 1 olaparib 1 cc-486 1 Trastuzumab 1 Thalidomide 1 Radiotherapy 1 Radiation 1 Platinum 1 Paclitaxel 1 Oxaliplatin 1 Observation 1 Nivolumab 1 Monatide (IMS 3015) 1 Methotrexate 1 Magnetic Resonance Imaging 1 Leucovorin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡